Compare GSK plc (GSK) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Keysight Technologies Inc — how do they compare? GSK plc trades at $46.87 (market cap $91.88B), while Keysight Technologies Inc trades at $380.3 (market cap $63.79B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Keysight Technologies Inc for 56 Days on average.
| GSK | KEYS | |
|---|---|---|
Market Cap | $91.88B | $63.79B |
Volume | 7,730,529 | 1,435,384 |
Sector | Health | Technology |
52-Week High | $61.18 | $387.90 |
52-Week Low | $43.24 | $159.49 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $111.88B | $63.93B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
Keysight Technologies (KEYS) trades at $381.49, down 1.65% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $3.07. The stock shows a bullish technical trend, trading near the pivot point of $380 with support at $377. Revenue for 2025 reached $5.38B, with net income of $850M, and the company is actively advancing in AI infrastructure and 6G testing, as highlighted in recent product launches and collaborations.
Outlook remains positive with a consensus price target of $416.63, representing a 9.2% upside, supported by accelerating earnings and strong AI demand. Risks include high valuation multiples, such as a P/E of 51.61, and supply constraints that may limit near-term revenue conversion despite surging orders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
